Brotizolam and cognitive performance: A double-blind, crossover study versus placebo in a population of shift workers

G. L. Gigli, M. C E Maschio, M. Diomedi, M. Moroni, S. Dell'orso, F. Placidi, M. G. Marciani

Research output: Contribution to journalArticle

Abstract

Evaluation of the residual effects of brotizolam on cognitive performance in subjects with circadian rhythm disorders (shift workers) was the aim of this double-blind crossover study. Thirteen shift workers (mean age, 27.9 years), who reported episodes of daytime insomnia, entered the final evaluation; three other subjects were withdrawn due to lack of compliance. During the two 15-day treatment periods, each subject received brotizolam 0.25 mg/day and placebo immediately before going to bed for the night or before their longest period of sleep during the day after the night shift. The two treatments were separated by a 15-day washout period. A battery of six neuropsychological tests (ie, Rey's test for verbal memory, auditory attention test, visual attention test, simple reaction test, test of lateralized letter reading, the test of lateralized visual pattern detection), performed at baseline and repeated after acute (day 1) and chronic (day 15) administration, demonstrated that with brotizolam the subjects did not develop residual effects that would significantly impair their performance, either compared with the baseline values or with placebo. The study results indicate that brotizolam may be considered to be a safe compound in the treatment of insomnia in patients with circadian rhythm disorders.

Original languageEnglish
Pages (from-to)129-136
Number of pages8
JournalCurrent Therapeutic Research
Volume53
Issue number2
DOIs
Publication statusPublished - 1993

Fingerprint

brotizolam
Double-Blind Method
Cross-Over Studies
Chronobiology Disorders
Placebos
Sleep Initiation and Maintenance Disorders
Population
Neuropsychological Tests
Compliance
Reading
Sleep
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Brotizolam and cognitive performance : A double-blind, crossover study versus placebo in a population of shift workers. / Gigli, G. L.; Maschio, M. C E; Diomedi, M.; Moroni, M.; Dell'orso, S.; Placidi, F.; Marciani, M. G.

In: Current Therapeutic Research, Vol. 53, No. 2, 1993, p. 129-136.

Research output: Contribution to journalArticle

Gigli, G. L. ; Maschio, M. C E ; Diomedi, M. ; Moroni, M. ; Dell'orso, S. ; Placidi, F. ; Marciani, M. G. / Brotizolam and cognitive performance : A double-blind, crossover study versus placebo in a population of shift workers. In: Current Therapeutic Research. 1993 ; Vol. 53, No. 2. pp. 129-136.
@article{62f11007f8a24dcbb0413fcdfecce512,
title = "Brotizolam and cognitive performance: A double-blind, crossover study versus placebo in a population of shift workers",
abstract = "Evaluation of the residual effects of brotizolam on cognitive performance in subjects with circadian rhythm disorders (shift workers) was the aim of this double-blind crossover study. Thirteen shift workers (mean age, 27.9 years), who reported episodes of daytime insomnia, entered the final evaluation; three other subjects were withdrawn due to lack of compliance. During the two 15-day treatment periods, each subject received brotizolam 0.25 mg/day and placebo immediately before going to bed for the night or before their longest period of sleep during the day after the night shift. The two treatments were separated by a 15-day washout period. A battery of six neuropsychological tests (ie, Rey's test for verbal memory, auditory attention test, visual attention test, simple reaction test, test of lateralized letter reading, the test of lateralized visual pattern detection), performed at baseline and repeated after acute (day 1) and chronic (day 15) administration, demonstrated that with brotizolam the subjects did not develop residual effects that would significantly impair their performance, either compared with the baseline values or with placebo. The study results indicate that brotizolam may be considered to be a safe compound in the treatment of insomnia in patients with circadian rhythm disorders.",
author = "Gigli, {G. L.} and Maschio, {M. C E} and M. Diomedi and M. Moroni and S. Dell'orso and F. Placidi and Marciani, {M. G.}",
year = "1993",
doi = "10.1016/S0011-393X(05)80237-1",
language = "English",
volume = "53",
pages = "129--136",
journal = "Current Therapeutic Research - Clinical and Experimental",
issn = "0011-393X",
publisher = "Excerpta Medica",
number = "2",

}

TY - JOUR

T1 - Brotizolam and cognitive performance

T2 - A double-blind, crossover study versus placebo in a population of shift workers

AU - Gigli, G. L.

AU - Maschio, M. C E

AU - Diomedi, M.

AU - Moroni, M.

AU - Dell'orso, S.

AU - Placidi, F.

AU - Marciani, M. G.

PY - 1993

Y1 - 1993

N2 - Evaluation of the residual effects of brotizolam on cognitive performance in subjects with circadian rhythm disorders (shift workers) was the aim of this double-blind crossover study. Thirteen shift workers (mean age, 27.9 years), who reported episodes of daytime insomnia, entered the final evaluation; three other subjects were withdrawn due to lack of compliance. During the two 15-day treatment periods, each subject received brotizolam 0.25 mg/day and placebo immediately before going to bed for the night or before their longest period of sleep during the day after the night shift. The two treatments were separated by a 15-day washout period. A battery of six neuropsychological tests (ie, Rey's test for verbal memory, auditory attention test, visual attention test, simple reaction test, test of lateralized letter reading, the test of lateralized visual pattern detection), performed at baseline and repeated after acute (day 1) and chronic (day 15) administration, demonstrated that with brotizolam the subjects did not develop residual effects that would significantly impair their performance, either compared with the baseline values or with placebo. The study results indicate that brotizolam may be considered to be a safe compound in the treatment of insomnia in patients with circadian rhythm disorders.

AB - Evaluation of the residual effects of brotizolam on cognitive performance in subjects with circadian rhythm disorders (shift workers) was the aim of this double-blind crossover study. Thirteen shift workers (mean age, 27.9 years), who reported episodes of daytime insomnia, entered the final evaluation; three other subjects were withdrawn due to lack of compliance. During the two 15-day treatment periods, each subject received brotizolam 0.25 mg/day and placebo immediately before going to bed for the night or before their longest period of sleep during the day after the night shift. The two treatments were separated by a 15-day washout period. A battery of six neuropsychological tests (ie, Rey's test for verbal memory, auditory attention test, visual attention test, simple reaction test, test of lateralized letter reading, the test of lateralized visual pattern detection), performed at baseline and repeated after acute (day 1) and chronic (day 15) administration, demonstrated that with brotizolam the subjects did not develop residual effects that would significantly impair their performance, either compared with the baseline values or with placebo. The study results indicate that brotizolam may be considered to be a safe compound in the treatment of insomnia in patients with circadian rhythm disorders.

UR - http://www.scopus.com/inward/record.url?scp=0027415755&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027415755&partnerID=8YFLogxK

U2 - 10.1016/S0011-393X(05)80237-1

DO - 10.1016/S0011-393X(05)80237-1

M3 - Article

AN - SCOPUS:0027415755

VL - 53

SP - 129

EP - 136

JO - Current Therapeutic Research - Clinical and Experimental

JF - Current Therapeutic Research - Clinical and Experimental

SN - 0011-393X

IS - 2

ER -